News ArticleLloyds Metals and Energy Announces Q2 and H1 FY 2026-27 Financial Results and Approves 360 MW Thermal Plant and Renewable Energy Investments
Company plans up to USD 300 million debt raise and grants over 13 lakh employee stock options; approves Rs. 625 crore investment in subsidiary Thriveni Earthmovers
Lloyds Metals and Energy Limited disclosed its unaudited standalone and consolidated financial results for Q2 and H1 ended 30th September 2026. The company also approved strategic investments including a 360 MW thermal power plant in Maharashtra, renewable energy projects, further investment in its subsidiary Thriveni Earthmovers, and proposed raising up to USD 300 million through debt issuance.
Lloyds Metals and Energy Limited
General / Other
Lloyds Metals and Energy Limited reported its unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2026 and approved key strategic initiatives including a 360 MW thermal power plant in Maharashtra and investments in renewable energy projects.
The Board of Directors approved the unaudited financial statements reviewed by the Audit Committee, covering both standalone and consolidated results for Q2 and H1 FY 2026-27, accompanied by a Limited Review Report from statutory auditors.
Lloyds Metals and Energy granted 62,000 employee stock options under the 2017 ESOP plan and 13,08,571 options under the 2024 ESOP scheme, aiming to incentivize employees.
Strategic capital expenditure includes establishing a 2×180 MW thermal power plant at Konsari, Maharashtra, intended primarily to serve the company's integrated operations at Hedri and Konsari.
Additionally, the company approved investing up to a 30% stake in renewable energy projects to procure 168 MW of power through captive consumption, aligning with sustainable energy objectives.
The Board also sanctioned subscribing up to Rs. 625 crore in further capital of subsidiary Thriveni Earthmovers and Infra Private Limited through rights or other capital issues, to be executed in one or more tranches as deemed fit by the subsidiary's management and Board of Directors of Lloyds Metals and Energy Limited separately approving the terms and timing of such investments before subscription is made by the company in such rights/further issues as per SEBI Regulations and law.
Highlights
- Unaudited Q2 & H1 FY 2026-27 financial results approved with limited review by auditors.
- Grant of over 13 lakh employee stock options under two ESOP schemes.
- Approval granted for setting up 360 MW thermal power plant in Konsari, Maharashtra.
- Up to 30% stake investment authorized in renewable energy projects for 168 MW power procurement.
- Investment up to Rs. 625 crore approved in Thriveni Earthmovers' capital through rights/further issues.
- Approved raising up to USD 300 million via USD notes and/or INR non-convertible debentures in multiple tranches.
Key Data Snapshot
What happened
- Lloyds Metals and Energy disclosed unaudited financial results for Q2 and H1 FY 2026-27 with a limited review report from auditors.
- The company approved substantial employee stock option grants under its 2017 and 2024 ESOP schemes.
- The Board authorized a 360 MW thermal power plant project at Konsari, Maharashtra, to fulfill internal power needs.
- Investment plans include up to a 30% stake in renewable energy projects to procure 168 MW via captive power arrangements.
- An investment up to Rs. 625 crore in the subsidiary Thriveni Earthmovers through subscribing to its rights or further capital issues was approved.
- The Board approved raising funds up to USD 300 million through issuance of USD-denominated notes and/or INR non-convertible debentures.
Transaction details
- Employee stock options granted total 13,70,571 across two ESOP schemes.
- Thermal power plant consists of two units of 180 MW each at Konsari to serve integrated operations.
- Renewable energy investments will be implemented in tranches; exact terms subject to future Board approvals.
- The subsidiary investment in Thriveni Earthmovers will proceed in one or more tranches with terms approved by both Boards.
- Fundraising includes senior secured/unsecured fixed or floating rate debt securities issued in single or multiple tranches.
- All major approvals are subject to applicable regulatory and statutory clearances.
Regulatory and governance context
- The financial results were approved in compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
- Limited Review Report was conducted by independent auditors in accordance with Indian Accounting Standards and applicable review standards.
- Disclosures include utilization certificates and security cover certificates as mandated under SEBI regulations.
- Investment and fundraising approvals are subject to requisite approvals and regulatory compliances.
- The company continues adherence to SEBI regulations for employee stock option disclosures and debt issuances.
Highlights
- Unaudited Q2 & H1 FY 2026-27 financial results approved with limited review by auditors.
- Grant of over 13 lakh employee stock options under two ESOP schemes.
- Approval granted for setting up 360 MW thermal power plant in Konsari, Maharashtra.
- Up to 30% stake investment authorized in renewable energy projects for 168 MW power procurement.
- Investment up to Rs. 625 crore approved in Thriveni Earthmovers' capital through rights/further issues.
- Approved raising up to USD 300 million via USD notes and/or INR non-convertible debentures in multiple tranches.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024
- Indian Accounting Standard 34 (Ind AS 34)
- Companies Act, 2013
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Biocon Limited Reports Q2 FY2027 Profit of Rs. 917 Million and Announces New CTO Appointment
Biocon Limited disclosed its unaudited standalone financial results for the quarter and half year ending September 30, 2026, with a quarterly profit of Rs. 917 million. The board also approved the resignation of CTO Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as CTO starting January 1, 2027.
Read Full Story
Biocon Reports Q2 FY27 Total Income of Rs 4,423 Crore With Biopharma Revenue Up 5% and $400 Million Pertuzumab Deal
Biocon Limited announced consolidated total income of Rs 4,423 crore for the second quarter of fiscal year 2027, with biopharma revenues increasing by 5% year-on-year to Rs 3,583 crore. The company's EBITDA was reported at Rs 865 crore and net profit at Rs 41 crore. A significant highlight includes securing a 10-year biosimilar Pertuzumab PDP partnership in Brazil valued at about USD 400 million.
Read Full Story
Zydus Lifesciences Posts Rs. 79,096 Million Revenue in Q2 FY27 with Net Profit at Rs. 9,255 Million
Zydus Lifesciences Limited reported strong revenue growth of 29% year-on-year in Q2 FY27 at Rs. 79,096 million, driven by its branded pharma businesses in India, North America, and international markets. However, net profit declined 27% to Rs. 9,255 million, and EBITDA dropped 6% to Rs. 18,945 million, reflecting cost and margin pressures.
Read Full Story
